94% of brain disease drugs fail — most blocked at the blood-brain barrier. Behind every failure, a family is still waiting. We find the ones that reach the brain — in silico, in days, not decades.
Molecules don't fail because they don't bind. They fail because they never arrive. We engineered around delivery — not around docking.
A mouse hit isn't a human hit. We simulate across 10 species so the surprises happen on a server — not in a Phase I.
Parallel discovery for canine cognitive dysfunction, epilepsy and anxiety — a faster regulatory path that generates dual-species validation data alongside the human pipeline.
A closed-loop translational intelligence platform. 10,000+ CNS targets across 791 indications and 10 species models. From concept to clinic, every decision is computed, validated and ranked.
Six engines, sixty-five gates, one ruthless principle: every candidate gets one chance to disqualify itself before it advances. Fail at gate 21 — not at clinical month thirty-six.
Most pipelines spend their compute on docking — the gate that arrives in month thirty-six. NPE inverts the order: causality, BBB transport and ADMET come before any physics-heavy run, so the 90+% of molecules that were never going to make it are dropped on day one.
Built in Switzerland. Engineered around one conviction: the Blood-Brain Barrier is a solvable computational problem — and CNS doesn't have to mean a 94% failure rate.
Most CNS molecules don't fail because they don't bind. They fail because they never reach the brain. The Blood-Brain Barrier is where billion-dollar programs go to fail — usually in Phase II, after the chemistry already worked. The industry treats delivery as a late-stage surprise; we treat it as gate one.
NeuroPrecision-Engine is the discovery stack engineered around the brain barrier from the first line of code. Real physics, real biology, CNS-trained machine learning, QM/MM physics-based scoring where classical methods lose resolution. No LLM wrappers. Real numbers, every gate.
A science-and-technology founding pair. One Chief Scientist, one Chief Technologist — sharing one conviction: the brain barrier is solvable, and CNS deserves a discovery stack engineered for it from the first line of code.
Designs the 65-gate pipeline from first principles. Owns target selection, BBB biology, validation strategy and pharma relationships.
Translates the pipeline into a live, GPU-accelerated system. Owns infrastructure, frontend, deployment, integrations and 24/7 operations.
Co-founder and platform architect. Designed the 65-gate pipeline from first principles and leads the science: target selection, BBB biology, validation strategy and pharma relationships.
Co-founder and technology lead. Translated the pipeline into a live, GPU-accelerated system and runs the engineering: infrastructure, frontend, deployment, integrations and 24/7 operations.
Most CNS failures are failures of delivery, not of chemistry. We moved that question to the beginning of the pipeline — modelled through physics, biology, machine learning and QM/MM physics-based scoring, gate by gate. Built in Sursee, Switzerland.
Amazon Web Services · Park Hyatt Zurich, Beethovenstrasse 21
Attending in person: Suvija Münow-Suthakaran — AWS-hosted full-day symposium for life-sciences R&D (8:30 AM – 3:40 PM CEST), followed by networking reception (3:40 – 6:00 PM CEST).
Event details →CHUV Biomedical Data Science Center · Directorate of Innovation and Clinical Research
Poster: "NeuroPrecision-Engine: A Closed-Loop AI Framework for CNS Drug Discovery" — presenting the 65-gate pipeline and the 10-species translation framework. Keynotes: Jonah Cool (Anthropic), Shirley Liu (GV20 Therapeutics), Pranav Rajpurkar (Harvard).
Symposium programme →Pharma. Biotech. Academia. CROs. Bring us a target, a disease, or a question — we'll show you the answer in days, not quarters.
Tell us the indication or target class — we'll get back to you within 48 hours.
Drop us a line and propose up to three times that work for you. We'll confirm one of them by email — usually within 24 business hours.
We'll confirm one of your proposed times by email — usually within 24 business hours.
All 791 indications carry human ICD-10 codes — the regulatory anchor. Search by disease name, ID, ICD-10 code, or target gene.
Try a different keyword, ICD-10 prefix, or target gene name.
Pick one of 791 indications. The Engine harvests the targets, builds the compound library, and runs all 65 gates against that disease's biology — automatically.
Type a name or ICD-10 — Glioblastoma, Alzheimer's, Rett syndrome, anything in the catalog.
Open Targets ≥0.4 association + STRING-PPI hop-2 + UniProt cross-refs build the target list — no manual seed needed.
ChEMBL bioactivity (pchembl ≥4.0) for the top targets, plus PubChem CNS focus set, plus DrugBank ATC N0x — deduplicated by InChIKey.
BBB filter first, then ADMET, then docking, then QM/MM scoring — fail-fast at every step. Final dossier in days, not quarters.
Already know the protein? Type its symbol or UniProt ID. The Engine harvests every known ligand, generates new ones, and runs all 65 gates around that single target.
Symbol (EGFR, SNCA, GBA1, LRRK2, MAPT, BACE1…) or UniProt accession — anything druggable.
UniProt → AlphaFold v6 + every PDB drug-bound template the target has. Class-aware: kinase, GPCR, ion-channel each handled differently.
Pull every known active from PubChem and ChEMBL, expand chemical space with structure-aware generation, and dedup.
Same gate sequence as a disease run — but every result is anchored to your one target. Top-10 lead dossier ranked by ΔG, BBB, safety, and novelty.
A drug that works in a mouse fails in humans 89% of the time. We close that gap by simulating across the entire evolutionary tree — and combining the signals into a single human-translation score.
PBPK with species-specific brain compartments + transporter expression.
Sequence + structural conservation of the target between species.
Each species' signal becomes a posterior. We fuse them into a single Translation Reliability Score with a calibrated confidence interval — that's the number that goes in the dossier.
NeuroPrecision-Engine KLG is a Swiss general partnership (Kollektivgesellschaft, Art. 552 ff. of the Swiss Code of Obligations) registered with the Commercial Register of the Canton of Lucerne under UID CHE-481.613.639 (SHAB 04.06.2026, notification HR01-1006667181). The controller for data processing on this Website within the meaning of Art. 5 lit. j of the Swiss Federal Act on Data Protection (FADP, SR 235.1) and, where applicable, Art. 4(7) GDPR is NeuroPrecision-Engine KLG, Schellenrainstrasse 7, 6210 Sursee, Switzerland. Partners with joint signing authority by two (Kollektivunterschrift zu zweien): Suvija Münow-Suthakaran and Tahnee Jessica Münow. Privacy enquiries: info@neuroprecision-engine.com.
This Privacy Policy applies to your interaction with the Website neuroprecision-engine.com, including (a) the simple Contact form, (b) the "Request a Pilot" form, (c) the disease catalogue and (d) any direct email correspondence with us at info@ / contact@ / privacy@neuroprecision-engine.com. It also covers the third-party hosting and form-processing infrastructure we use on our behalf. It does not cover third-party websites linked from this Website (see §15).
3.1 Personal Information you actively provide via the Contact or Pilot forms: first and last name, work email, organisation, role (optional), country/region, message content, proposed meeting slots (date, time, timezone, platform preference), and cookie-consent confirmation. When you write to us directly, we receive whatever your email contains.
3.2 Technical Information automatically collected by our hosting provider and our form-processing infrastructure: IP address (truncated where feasible), browser type and version, operating system, request timestamp, referring URL, requested page. Used solely for security (DDoS detection, intrusion prevention), error monitoring and aggregate visit statistics — never for individual tracking or profiling.
3.3 Local browser storage (localStorage): two values are stored ON YOUR DEVICE — npe_cookie_consent (your accept/decline choice) and npe_lang (interface language). These are not transmitted to us. You can delete them at any time via your browser settings.
3.4 What we explicitly do NOT collect: Google Analytics, Mixpanel, Hotjar, FullStory or any analytics SDK; marketing or advertising cookies; cross-site tracking pixels; browser fingerprinting (Canvas / WebGL / audio context / installed fonts); social-media plugins (Facebook Like, LinkedIn share, X embeds); third-party retargeting or programmatic ad networks; Geolocation API; Device Sensor APIs. Our Website is intentionally minimal in this regard.
We use your Personal Information only for the following purposes: (a) to respond to your enquiry, (b) to schedule and conduct the meeting you propose, (c) to document the exchange for our records under Art. 957–958f CO (commercial record-keeping obligation), (d) to send you the specific information or follow-up scientific data you requested (where applicable, under NDA). We do NOT use your data to send unsolicited marketing, to build behavioural profiles, to train ML models for any purpose other than scientific computation you have specifically commissioned, or to transfer to data brokers.
NeuroPrecision-Engine KLG develops a computational drug-discovery platform and delivers pipeline-derived outputs (target dossiers, lead candidates, validation reports) to its partners and customers. We do not maintain a marketing email list, send promotional newsletters, run drip campaigns or purchase contact lists. Any communication you receive from us is a direct response to your enquiry. If you no longer wish to hear from us, simply reply with "Unsubscribe" or contact info@neuroprecision-engine.com.
6.1 Service Providers (Data Processors). We use trusted third-party processors who handle your data on our behalf under written Data Processing Agreements (DPA), covering: website hosting (static-site delivery and CDN), serverless form processing, and transactional email delivery. Our processors are certified under the Swiss-EU Data Privacy Framework (DPF) where applicable, and we have signed EU Standard Contractual Clauses (SCC) for any data flows outside the EEA. We do not currently use any CRM, helpdesk, marketing-automation or customer-data platform.
6.2 Affiliates. NeuroPrecision-Engine KLG has no parent company, subsidiary or affiliated entity. We do not share data with affiliates because there are none.
6.3 Law Enforcement and Legal Obligations. We may disclose Personal Information when required by a valid Swiss court order, FDPIC enquiry, or other binding legal process. We will notify you of such disclosure unless legally prohibited from doing so.
6.4 Corporate Transactions. In the event of a merger, acquisition, asset sale, joint venture or restructuring, your Personal Information may be transferred to the successor entity. We will notify you by email (where we have one on file) and on this page at least 30 days before any such transfer becomes effective, and the successor entity will be bound by this Privacy Policy or a substantively equivalent policy.
6.5 No Sale, No Profiling. We do not sell Personal Information to third parties and do not engage in automated decision-making with legal or similarly significant effect on you (Art. 22 GDPR).
Processing of your Personal Information rests on: Art. 6(1)(a) GDPR / Art. 31(1) revFADP (your consent — cookie banner, form submission); Art. 6(1)(b) GDPR (performance of a contract or pre-contractual measures, e.g. Pilot Request); Art. 6(1)(c) GDPR / Art. 957–958f CO (commercial record-keeping); Art. 6(1)(f) GDPR / Art. 31(1)(c) revFADP (legitimate interests: security, fraud prevention, IT operations).
Contact-form and Pilot-request data: retained for as long as necessary to respond and document the exchange — in any event no longer than the 10-year period required by Art. 957–958f CO commercial record-keeping. Hosting access logs: rotated and deleted on a 90-day rolling basis. Form-processing logs: 30-day rolling basis. Cookie-consent record (localStorage): until you clear it. Aggregate, non-identifying statistics: may be retained indefinitely. You may request earlier deletion at any time (§11).
Your Personal Information may be transferred to and processed in: Switzerland (our registered seat, Sursee) and the European Economic Area (EEA), and — where our infrastructure providers operate — in other jurisdictions outside the EEA. Any cross-border transfer to a country without an adequacy decision is governed by (1) the Swiss-EU Data Privacy Framework where applicable to the processor, (2) EU Standard Contractual Clauses (SCC) signed with the processor, and (3) your explicit consent via our cookie banner where required. We have performed a Transfer Impact Assessment in line with the FDPIC and EDPB guidance and consider the transfer to provide an equivalent level of protection under Art. 16 ff. revFADP.
On your first visit, this Website displays a cookie consent banner asking you to Accept or Decline. We use only strictly necessary technical storage (browser localStorage) for two purposes: (a) remembering your language preference (EN / DE / FR) and (b) remembering your cookie-consent choice so the banner does not reappear on every visit. We do not set marketing, advertising, analytics or cross-site tracking cookies, and we do not embed third-party tracking pixels, internet tags, web beacons or social plugins. You can withdraw your consent at any time by clearing your browser storage for this domain (browser settings → site data → clear), which will cause the consent banner to reappear on your next visit. Legal basis: Art. 6(1)(a) GDPR (consent) and Art. 31(1) revFADP (consent) where applicable; storage of consent and language preference qualifies as «strictly necessary» under Art. 5(3) ePrivacy Directive.
11.1 Under Swiss revFADP (SR 235.1): Right of access (Art. 25); right to rectification (Art. 32); right to erasure / "be forgotten" (Art. 32(2)(c)); right to data portability (Art. 28); right to object to automated decision-making (Art. 21).
11.2 Under EU GDPR (additionally, where applicable): access (Art. 15), rectification (Art. 16), erasure (Art. 17), restriction of processing (Art. 18), data portability (Art. 20), objection (Art. 21), withdraw consent at any time without retroactive effect (Art. 7(3)), and not to be subject to a decision based solely on automated processing (Art. 22).
11.3 How to exercise your rights: send a request to info@neuroprecision-engine.com or to the future privacy-specific address privacy@neuroprecision-engine.com. We will respond within 30 days. We may need to verify your identity before fulfilling the request.
11.4 Right to lodge a complaint: Switzerland — Federal Data Protection and Information Commissioner (FDPIC / EDÖB), Feldeggweg 1, 3003 Bern, www.edoeb.admin.ch. EU — your local Data Protection Authority. UK — Information Commissioner's Office (ICO), www.ico.org.uk.
We implement reasonable technical and organisational measures: TLS 1.3 encryption in transit (HSTS enforced site-wide); AES-256 encryption at rest using managed encryption keys; least-privilege identity and access controls; SHA-256 cryptographic hashes for data-integrity attestation; SLSA-3 build provenance for the pipeline; 7-year immutable audit-trail storage (Object-Lock equivalent); cosign-signed container images; isolation of contact-form data from the scientific pipeline (no Personal Information ever enters the scientific compute path). No system or online transmission can be guaranteed 100% secure. We will notify affected users and the FDPIC of any security incident as required by Art. 24 revFADP and Art. 33–34 GDPR.
Although we do not engage in any cross-site or behavioural tracking, we honour browser DNT signals where present. Since we use only essential first-party storage, your DNT setting has no further behavioural impact on our processing — but it is respected as a transparent signal of your preference.
The Website and its services are intended exclusively for adult professionals working in pharmaceutical research, biotechnology, academia, regulatory affairs and related life-sciences fields. We do not knowingly collect Personal Information from minors under 18 years of age. If you believe a minor has provided Personal Information via the Website, please contact us at info@neuroprecision-engine.com and we will delete it immediately.
The Website contains links to external resources including but not limited to: NVIDIA (BioNeMo, Inception), ChEMBL, UniProt, ClinicalTrials.gov, AlphaFold-DB, RCSB PDB, PubMed, NIH GEO, LinkedIn (founder profiles), GitHub, Royal Society of Medicine. We have no control over the content or privacy practices of these third parties. Please review their privacy policies before providing any Personal Information to them.
NeuroPrecision-Engine KLG is established in Switzerland. As a Swiss SME providing a computational drug-discovery platform and its outputs to professional partners and customers, our processing of personal data from EU/EEA data subjects is occasional, of small volume, and limited to contact-form submissions and B2B correspondence. Pursuant to Art. 27(2)(a) GDPR — derogation for occasional processing that does not include large-scale or special-category data — we currently do not appoint an EU representative. EU/EEA data subjects may contact us directly at info@neuroprecision-engine.com to exercise their rights and we will respond within the statutory 30-day period. We will appoint an EU representative if our processing volume or nature changes such that the derogation no longer applies, and will update this Privacy Policy accordingly.
The same reasoning as §16 applies under UK GDPR. NPE relies on the Art. 27(2)(a) UK GDPR derogation for occasional processing. UK data subjects may contact us directly at info@neuroprecision-engine.com. The UK supervisory authority is the Information Commissioner's Office (ICO), www.ico.org.uk.
In addition to the FADP, your personality rights are protected under Art. 28 of the Swiss Civil Code (ZGB, SR 210). Any infringement caused by data processing on this Website may be the subject of a personality-rights action under Swiss law.
General enquiries: info@neuroprecision-engine.com
Privacy / data subject requests: info@neuroprecision-engine.com (privacy-specific address privacy@neuroprecision-engine.com being configured)
Partnership / pharma enquiries: contact@neuroprecision-engine.com
Postal: NeuroPrecision-Engine KLG, Schellenrainstrasse 7, 6210 Sursee, Canton Lucerne, Switzerland
We may update this Privacy Policy periodically to reflect changes in our practices, technology, applicable law or other factors. The current version applicable to your visit is always the version published on this page on the date of that visit. Material changes will be communicated by a banner notice on the Website for at least 30 days, and where you have provided a contact email, by email.
Version 3.0 — Last updated: June 2026, Sursee, Switzerland.
NeuroPrecision-Engine KLG is a Swiss general partnership (Kollektivgesellschaft, Art. 552 ff. of the Swiss Code of Obligations, CO/OR, SR 220) with registered seat at Schellenrainstrasse 7, 6210 Sursee, Canton Lucerne, Switzerland, registered with the Commercial Register of the Canton of Lucerne under UID CHE-481.613.639 (Tagesregister-Nr. 5408 of 01.06.2026; SHAB publication 04.06.2026, notification HR01-1006667181; commencement of the partnership 15.05.2026). The partnership has legal capacity to act, sue and be sued (Art. 562 CO); the partners are subsidiarily, jointly and severally personally liable after exhaustion of partnership assets (Art. 568 CO). Both partners sign jointly by two (Kollektivunterschrift zu zweien):
General contact: info@neuroprecision-engine.com · Partnership / pharma enquiries: contact@neuroprecision-engine.com
Schellenrainstrasse 7, 6210 Sursee, Canton Lucerne, Switzerland
Content on this website is provided in good faith for informational purposes and does not constitute a medical, scientific, regulatory or investment recommendation. No warranty is given regarding accuracy, completeness or timeliness. NeuroPrecision-Engine KLG excludes liability to the maximum extent permitted by Art. 100 and Art. 101 CO. External links lead to third-party websites over which the partnership has no influence and accepts no responsibility.
All content, design elements, text, images, source code, the NPE wordmark, the 65-gate pipeline architecture and the 791-disease catalogue on this website are the intellectual property of NeuroPrecision-Engine KLG or used with permission of the rights holders. Reproduction, modification, public display or commercial use, in whole or in part, without prior written consent is not permitted (Art. 9 ff. URG, SR 231.1; Art. 28 / 29 ZGB; Art. 1 MSchG, SR 232.11).
This Website and its use are governed exclusively by Swiss substantive law (CO / OR, SR 220; ZGB, SR 210; FADP, SR 235.1; URG, SR 231.1; MSchG, SR 232.11). Sole place of jurisdiction is the competent court at the seat of NeuroPrecision-Engine KLG in Sursee, Canton Lucerne, Switzerland (Art. 32 ZPO, SR 272), subject to mandatory consumer-protection forums under the visitor's domicile law where applicable. The full Terms apply — see our AGB.
These General Terms and Conditions ("AGB") govern access to and use of the website neuroprecision-engine.com (the "Website") and any pre-contractual or contractual communication with the operator. They are governed by Swiss law, in particular the Swiss Code of Obligations (CO / OR, SR 220), the Swiss Civil Code (ZGB, SR 210) and the Swiss Federal Act on Data Protection (FADP, SR 235.1).
The Website is operated by NeuroPrecision-Engine KLG, a Swiss general partnership (Kollektivgesellschaft, Art. 552 ff. CO) with registered seat at Schellenrainstrasse 7, 6210 Sursee, Canton Lucerne, Switzerland, registered with the Commercial Register of the Canton of Lucerne under UID CHE-481.613.639 (SHAB 04.06.2026, HR01-1006667181). Partners with joint signing authority by two (Kollektivunterschrift zu zweien) are Suvija Münow-Suthakaran and Tahnee Jessica Münow. All contractual statements and binding offers originate from the KLG; the partners are subsidiarily, jointly and severally personally liable under Art. 568 CO.
These AGB apply to every visitor and user of the Website. By accessing the Website you accept these terms in the version available at the time of your visit. The operators may amend these AGB at any time; the version applicable to a given visit is the version published on this page on the date of that visit.
All content on the Website (including, without limitation, descriptions of the 65-gate pipeline, statistical figures, disease catalogue, in-silico results, illustrations and screenshots) is provided for general information and demonstration purposes only. It is not a medical, scientific, regulatory, legal, financial or investment recommendation, and it does not replace independent professional advice. The Website does not constitute a binding offer (Art. 7 CO).
The operators take reasonable care in compiling and presenting the information on the Website, but make no warranty as to its accuracy, completeness, timeliness, fitness for a particular purpose, or non-infringement of third-party rights. In particular, computational results displayed on this Website are illustrative; running the actual pipeline on a given target or indication is required to obtain a binding scientific result.
To the fullest extent permitted by mandatory Swiss law (Art. 100 and Art. 101 CO), the operators exclude any liability for direct, indirect, incidental or consequential damages arising from access to or use of the Website, from reliance on its content, or from temporary unavailability or technical failure of the Website. Liability for unlawful intent or gross negligence remains reserved as required by Art. 100(1) CO.
The Website may contain links to third-party websites (e.g. UniProt, ChEMBL, ClinicalTrials.gov, AlphaFold-DB, NVIDIA NIM endpoints). The operators have no influence on the content, availability or data-protection practices of those third parties and accept no liability for their content. Following such links is at the visitor's own responsibility.
All content on the Website — including text, design elements, the NPE logo, source code, illustrations, screenshots, the 65-gate pipeline architecture and the 791-disease catalogue — is the intellectual property of the operators or used with permission of the respective rights holders. Reproduction, distribution, public display, modification, reverse engineering or commercial use, in whole or in part, requires the prior written consent of the operators (Art. 9 ff. of the Swiss Copyright Act, URG, SR 231.1; Arts. 28 and 29 ZGB regarding personality rights).
"NeuroPrecision-Engine", "NeuroPrecision-Engine KLG", "NPE" and the NPE wordmark are used by the operator as commercial designations within the meaning of Art. 1 of the Swiss Trademark Act (MSchG, SR 232.11) and as the registered firm name in the Commercial Register of the Canton of Lucerne. Use by third parties without prior written consent is not permitted.
Visitors and users undertake (a) not to attempt unauthorised access to non-public parts of the Website, (b) not to use the Website for any unlawful purpose or in a manner liable to damage the Website, the operators or third parties, (c) not to scrape, harvest or republish substantial parts of the disease catalogue or pipeline data without prior written consent, and (d) to refrain from any conduct contrary to public order or accepted morality (Art. 19 and Art. 20 CO).
The processing of personal data on this Website is governed by our Privacy Policy and complies with the Swiss Federal Act on Data Protection (FADP / nFADP, SR 235.1) and, where applicable, the EU General Data Protection Regulation (GDPR, Reg. (EU) 2016/679). See the Privacy Policy for details.
Should individual provisions of these AGB be or become invalid, void or unenforceable, the remaining provisions shall remain in full force and effect. The invalid provision shall be replaced by a valid provision that most closely matches the economic intent of the original provision, in accordance with Art. 20(2) CO.
These AGB and any non-contractual obligations arising from or in connection with the Website are governed exclusively by Swiss substantive law, with the express exclusion of conflict-of-laws rules and the United Nations Convention on Contracts for the International Sale of Goods (CISG). Sole place of jurisdiction is the competent court at the seat of NeuroPrecision-Engine KLG in Sursee, Canton Lucerne, Switzerland — subject to any mandatory consumer-protection forum a visitor may have under their Swiss or EU domicile law (Art. 32 of the Swiss Code of Civil Procedure, ZPO, SR 272; Art. 114 PILA, SR 291).
Version 2.0 — published June 2026, Sursee, Switzerland.
